Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Strongbridge Biopharma plc is a biotechnology business based in the US. Strongbridge Biopharma shares (SBBP) are listed on the NASDAQ and all prices are listed in US Dollars. Strongbridge Biopharma employs 71 staff and has a trailing 12-month revenue of around USD$28.1 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Casual investors
Latest market close | USD$3.055 |
---|---|
52-week range | USD$1.5 - USD$4.44 |
50-day moving average | USD$2.7368 |
200-day moving average | USD$2.8732 |
Wall St. target price | USD$8 |
PE ratio | 4.2673 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.621 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.055 from 2021-01-11
1 week (2021-01-11) | N/A |
---|---|
1 month (2020-12-18) | N/A |
3 months (2020-10-18) | N/A |
6 months (2020-07-18) | N/A |
1 year (2020-01-18) | N/A |
---|---|
2 years (2019-01-18) | N/A |
3 years (2018-01-18) | N/A |
5 years (2016-01-18) | N/A |
Valuing Strongbridge Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Strongbridge Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Strongbridge Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Strongbridge Biopharma shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | USD$28.1 million |
---|---|
Gross profit TTM | USD$17.9 million |
Return on assets TTM | -23.68% |
Return on equity TTM | -54.61% |
Profit margin | -149.8% |
Book value | $1.115 |
Market capitalisation | USD$199.7 million |
TTM: trailing 12 months
There are currently 705,043 Strongbridge Biopharma shares held short by investors – that's known as Strongbridge Biopharma's "short interest". This figure is 15.8% up from 608,835 last month.
There are a few different ways that this level of interest in shorting Strongbridge Biopharma shares can be evaluated.
Strongbridge Biopharma's "short interest ratio" (SIR) is the quantity of Strongbridge Biopharma shares currently shorted divided by the average quantity of Strongbridge Biopharma shares traded daily (recently around 371075.26315789). Strongbridge Biopharma's SIR currently stands at 1.9. In other words for every 100,000 Strongbridge Biopharma shares traded daily on the market, roughly 1900 shares are currently held short.
However Strongbridge Biopharma's short interest can also be evaluated against the total number of Strongbridge Biopharma shares, or, against the total number of tradable Strongbridge Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Strongbridge Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Strongbridge Biopharma shares in existence, roughly 10 shares are currently held short) or 0.0118% of the tradable shares (for every 100,000 tradable Strongbridge Biopharma shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Strongbridge Biopharma.
Find out more about how you can short Strongbridge Biopharma stock.
We're not expecting Strongbridge Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Strongbridge Biopharma's shares have ranged in value from as little as $1.5 up to $4.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Strongbridge Biopharma's is 1.9112. This would suggest that Strongbridge Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
Everything we know about the Grab IPO, plus information on how to buy in.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Everything we know about the Terns Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Angion Biomedica Corp IPO, plus information on how to buy in.
Everything we know about the PurposeBuilt Brands Inc IPO, plus information on how to buy in.
Everything we know about the Vor Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the LumiraDx Limited IPO, plus information on how to buy in.